Related Experiment Video
Updated: Dec 18, 2025
06:22
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
1.2K
5-Methoxyindole-2-Carboylic Acid (MICA) Fails to Retard Development and Progression of Type II Diabetes in ZSF1
Chun-Yan Li1,2, Wei-Xing Ma1,3,4, Liang-Jun Yan1
1Department of Pharmaceutical Sciences, UNT System College of Pharmacy, University of North Texas Health Science Center, Fort Worth, Texas 76107, USA.
Reactive Oxygen Species (Apex, N.C.)
|June 20, 2020
Summary
5-Methoxyindole-2-carboxylic acid (MICA) did not demonstrate anti-diabetic effects in ZSF1 rats. Further research is needed to understand MICA
Area of Science:
- Biochemistry
- Pharmacology
- Metabolic Diseases
Background:
- 5-Methoxyindole-2-carboxylic acid (MICA) is a known inhibitor of mitochondrial dihydrolipoamide dehydrogenase (DLDH).
- MICA exhibits neuroprotective properties against ischemic stroke in animal models.
- Previous studies suggest MICA as a potential antidiabetic agent, but mechanisms are unclear.
Purpose of the Study:
- To investigate the antidiabetic effects of MICA in the ZSF1 rat model of type 2 diabetes.
- To elucidate the underlying mechanisms of MICA's potential action in diabetes.
Main Methods:
- ZSF1 rats and healthy controls were administered a MICA-containing diet (200 mg/kg/day) or control diet for 9 weeks.
- Body weight changes and blood glucose levels were monitored throughout the study.
Main Results:
- MICA administration did not significantly alter body weight changes in ZSF1 rats compared to controls.
- MICA failed to reduce blood glucose levels in ZSF1 diabetic rats over the 9-week period.
Conclusions:
- MICA did not exhibit antidiabetic efficacy in the ZSF1 rat model under the tested conditions.
- The study highlights the need for further investigation into MICA's metabolic effects and potential mechanisms.
Related Concept Videos
01:22Diabetes Mellitus: Overview and Type I Subtype
4.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.7K
01:22Diabetes Mellitus: Type 2 and Gestational
4.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.2K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
515
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
515